TrialNCT07517263
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
- Status
- RECRUITING
- Phase
- PHASE3
- Last update posted
- 09/04/2026
- Start
- 05/11/2026
- Sponsor
- Novartis Pharmaceuticals
- Specialties
- cardiology, cross-cutting
Conditions: Cardiovascular Disease and Lipoprotein(a)
Brief summary
This open-label extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301).
Protocol documents and results are not hosted here. Verify every detail on ClinicalTrials.gov.